

Interview Summary	Application No.	Applicant(s)	
	09/724,552	SCHENK ET AL.	
	Examiner	Art Unit	
	Christopher Nichols, Ph.D.	1647	

All participants (applicant, applicant's representative, PTO personnel):

(1) Examiner Christopher Nichols, Ph.D.

(3) Rosemarie Celli.

(2) SPE Gary Kunz, Ph.D.

(4) Joe Liebeschuetz.

Date of Interview: 06 October 2003.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.

If Yes, brief description: _____.

Claim(s) discussed: 47 and 67-83.


Identification of prior art discussed: Walker et al. (July 1994) "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody." Journal of Neuropathology and Experimental Neurology 53(4): 377-383.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: (a) Chimeric, humanized, or human antibodies versus monoclonal mouse antibodies (10D5), (b) Diagnostic versus therapeutic methods and uses of antibodies, (c) Walker et al. does not disclose epitope of 10D5 antibody (SPE Kunz agrees that Walker et al. no longer qualifies as 35 U.S.C. 102(b) reference for instant claims).

** No Applicant summary deemed necessary.*

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


Examiner's signature, if required